Results 331 to 340 of about 1,827,024 (396)

Strengthening advanced therapy for sickle cell disease in Africa: experience from sickle cell disease centre in Dar es Salaam, Tanzania. [PDF]

open access: yesBMJ Glob Health
Bukini D   +19 more
europepmc   +1 more source

Underlying disease is the main risk factor in post‐splenectomy complication risk: Data from a national database

open access: yesBritish Journal of Haematology, Volume 206, Issue 6, Page 1811-1821, June 2025.
The association between underlying haematological disease, age at splenectomy and post‐splenectomy complications was explored among 1348 splenectomized patients, followed in 53 clinical centres with a median follow‐up time of 13 years and affected by transfusion‐dependent thalassaemia (TDT), non‐transfusion‐dependent thalassaemia (NTDT), sickle cell ...
Maddalena Casale   +44 more
wiley   +1 more source

Usage of a Multipurpose mHealth App Among Adults With Sickle Cell Disease: Randomized Controlled Trial. [PDF]

open access: yesJMIR Form Res
Cronin RM   +7 more
europepmc   +1 more source

The role of red blood cell characteristics and viscosity in sickle cell retinopathy and maculopathy

open access: yesBritish Journal of Haematology, Volume 206, Issue 6, Page 1796-1805, June 2025.
Sickle cell retinopathy and maculopathy are common ocular complications of sickle cell disease. This study assessed the contribution of red blood cell characteristics and blood viscosity to their development. HbSC patients with proliferative retinopathy showed a lower delta elongation index and point of sickling, while no link was found between whole ...
Rajani P. Brandsen   +8 more
wiley   +1 more source

Critical Roles for Modeling and Simulation and Real‐World Evidence to Inform Challenges in Clinical Trial Diversity Planning

open access: yesClinical and Translational Science, Volume 18, Issue 6, June 2025.
ABSTRACT Due to the highly controlled settings of clinical trials, enrolled subjects may not be fully representative in age, gender, ethnicity, medical status, or socioeconomic background of the variety of patients who will ultimately receive a medication. This disconnect can lead to post‐approval challenges, the most substantial of which could include
Ananth Kadambi   +7 more
wiley   +1 more source

Assessing Major Organ Dysfunction in Children With Sickle Cell Disease: Protocol for a Cross-Sectional Study. [PDF]

open access: yesHealth Sci Rep
Paintsil V   +13 more
europepmc   +1 more source

The Heat Is On: Climate Change Implications for Pregnant Women with Sickle Cell Disease. [PDF]

open access: yesWomens Health Rep (New Rochelle)
Chanmany Pastor R   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy